Shares of Synaptics Incorporated (NASDAQ:SYNA) jumped more than 19 percent in premarket trading Wednesday after the maker of touch-screen technology said it would buy smartphone and tablet chipmaker Renesas SP Drivers for $475 million. Synaptics, Incorporated (NASDAQ:SYNA) net profit margin is 6.70% and weekly performance is 0.26%. On last trading day company shares ended up $66.52. Analysts mean target price for the company is $80.00. Synaptics, Incorporated (NASDAQ:SYNA) distance from 50-day simple moving average (SMA50) is 7.86%.
Rambus Inc. (NASDAQ:RMBS) announced the CryptoManager™ platform, a feature management solution developed by the Rambus Cryptography Research (CRI) division. The CryptoManager platform consists of both a Security Engine and an Infrastructure suite that can dramatically improve efficiency and security during the manufacturing process. As lead customer, Qualcomm (see related release also issued today) is integrating the CryptoManager Security Engine into select SoCs and adopting the Infrastructure suite as part of its overall manufacturing process. Rambus Inc. (NASDAQ:RMBS) shares advanced 0.82% in last trading session and ended the day on $12.36. Gross Margin is 87.00% and its return on assets is -2.30%. Rambus Inc. (NASDAQ:RMBS) quarterly performance is 23.85%.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced that a Phase 2 proof-of-concept study in healthy volunteers demonstrated that andexanet alfa, a potential first-in-class Factor Xa inhibitor antidote, immediately reversed the anticoagulation activity of enoxaparin, a low molecular weight heparin and standard of care in venous thromboembolism prevention. Andexanet alfa was well tolerated with no serious adverse events reported. Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares moved up 1.22% in last trading session and was closed at $24.01, while trading in range of $22.18- $24.17. Portola Pharmaceuticals Inc (NASDAQ:PTLA) year to date (YTD) performance is -6.76%.
On May 27, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced its scheduled presentation at the investor conferences in June: JMP Securities Healthcare Conference 2014 on Wednesday, June 25, 2014, at 12:00 p.m. ET, in New York. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) ended the last trading day at $6.05. Company weekly volatility is calculated as 4.19% and price to cash ratio as 1.85. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) showed a positive weekly performance of 8.81%.
Prospect Capital Corporation (NASDAQ:PSEC) announced that based on our discussions with the staffs of the Division of Investment Management (“IM”) and the Office of the Chief Accountant (“OCA”) of the Securities and Exchange Commission (“SEC”), Prospect will not be required to restate its prior period financial statements to consolidate certain wholly-owned or substantially wholly-owned holding company subsidiaries. Prospect Capital Corporation (NASDAQ:PSEC) net profit margin is 47.60% and weekly performance is 1.66%. On last trading day company shares ended up $9.82. Analysts mean target price for the company is $11.68. Prospect Capital Corporation (NASDAQ:PSEC) distance from 50-day simple moving average (SMA50) is -4.40%.